Femasys Inc (FEMY)

$0.59 -0.01 (-1.53%)
Market Cap 34.78M
Revenue (ttm) 1.63M
Net Income (ttm) -18.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,154.60%
Debt to Equity Ratio 0.02
Volume 541,000
Avg Vol 4,684,848
Day's Range N/A - N/A
Shares Out 58.48M
Stochastic %K 33%
Beta -2.54
Analysts Strong Sell
Price Target $4.50

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 770 500 3910
Fax: 404 581 5903
Address:
3950 Johns Creek Court, Suite 100, Suwanee, United States
4RiskyBusiness4
4RiskyBusiness4 Jan. 14 at 1:34 PM
$FEMY Wouldn’t be surprised if a buy out is imminent. Extension is essentially automatic since they previously set expectations with the exchange.
0 · Reply
onethestiff
onethestiff Jan. 14 at 12:39 PM
$FEMY wouldn’t be surprised if a reverse split is coming
0 · Reply
Alican1994
Alican1994 Jan. 14 at 12:14 PM
$FEMY Maricones compren ya dejen de llorar
0 · Reply
Mirto
Mirto Jan. 14 at 11:04 AM
$FEMY welp. Waited forever for no extension and a stupid useless partnership? With no sales numbers? What a fvcking joke. Good job team. Worthless idiots.
1 · Reply
Severian1
Severian1 Jan. 14 at 12:31 AM
$FEMY Gimme a buyout this year baby!!!!!!!
0 · Reply
onethestiff
onethestiff Jan. 14 at 12:26 AM
$FEMY no extension news then?!
1 · Reply
wolfden2000
wolfden2000 Jan. 13 at 11:50 PM
$FEMY
0 · Reply
4RiskyBusiness4
4RiskyBusiness4 Jan. 13 at 9:24 PM
$FEMY It will take time, bit those holding in five years are likely to have big grins when they open their accounts.
1 · Reply
wolfden2000
wolfden2000 Jan. 13 at 7:57 PM
$FEMY When a clinic like Refuah receives federal funds from HRSA or similar agencies: • It must spend the funds according to the grant’s terms and conditions (which include allowable cost rules). • It must track and document how federal dollars are used, including payments to vendors. • It must report on use of funds, often through Federal Financial Reports (FFRs) and other reporting.  Read between the lines. This Trump administration, like them or not, is supporting infertility clinics. I bet they invest or support FEMY directly in 2026 with the declining birth rates. JMO.
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 7:25 PM
$FEMY eyes on support and bids!
0 · Reply
Latest News on FEMY
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Jan 13, 2026, 9:00 AM EST - 23 hours ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Dec 18, 2025, 9:15 AM EST - 26 days ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov 25, 2025, 9:15 AM EST - 7 weeks ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Nov 3, 2025, 8:30 AM EST - 2 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct 16, 2025, 9:00 AM EDT - 3 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 11, 2025, 9:00 AM EDT - 4 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep 8, 2025, 9:00 AM EDT - 4 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 25, 2025, 11:44 PM EDT - 5 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 4:05 PM EDT - 5 months ago

Femasys Announces Second Quarter Financial Results for 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Aug 6, 2025, 9:00 AM EDT - 5 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jul 1, 2025, 9:00 AM EDT - 7 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 25, 2025, 9:00 AM EDT - 7 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 17, 2025, 9:00 AM EDT - 7 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Jun 11, 2025, 9:00 AM EDT - 7 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025, 4:23 PM EDT - 8 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 5:01 PM EDT - 8 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 10 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 19, 2025, 9:20 AM EDT - 10 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 18, 2025, 9:00 AM EDT - 10 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Mar 13, 2025, 8:30 AM EDT - 10 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 25, 2025, 9:20 AM EST - 11 months ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Mar 6, 2024, 9:00 AM EST - 2 years ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 28, 2024, 9:00 AM EST - 2 years ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Feb 6, 2024, 8:30 AM EST - 2 years ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 26, 2024, 8:00 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

4RiskyBusiness4
4RiskyBusiness4 Jan. 14 at 1:34 PM
$FEMY Wouldn’t be surprised if a buy out is imminent. Extension is essentially automatic since they previously set expectations with the exchange.
0 · Reply
onethestiff
onethestiff Jan. 14 at 12:39 PM
$FEMY wouldn’t be surprised if a reverse split is coming
0 · Reply
Alican1994
Alican1994 Jan. 14 at 12:14 PM
$FEMY Maricones compren ya dejen de llorar
0 · Reply
Mirto
Mirto Jan. 14 at 11:04 AM
$FEMY welp. Waited forever for no extension and a stupid useless partnership? With no sales numbers? What a fvcking joke. Good job team. Worthless idiots.
1 · Reply
Severian1
Severian1 Jan. 14 at 12:31 AM
$FEMY Gimme a buyout this year baby!!!!!!!
0 · Reply
onethestiff
onethestiff Jan. 14 at 12:26 AM
$FEMY no extension news then?!
1 · Reply
wolfden2000
wolfden2000 Jan. 13 at 11:50 PM
$FEMY
0 · Reply
4RiskyBusiness4
4RiskyBusiness4 Jan. 13 at 9:24 PM
$FEMY It will take time, bit those holding in five years are likely to have big grins when they open their accounts.
1 · Reply
wolfden2000
wolfden2000 Jan. 13 at 7:57 PM
$FEMY When a clinic like Refuah receives federal funds from HRSA or similar agencies: • It must spend the funds according to the grant’s terms and conditions (which include allowable cost rules). • It must track and document how federal dollars are used, including payments to vendors. • It must report on use of funds, often through Federal Financial Reports (FFRs) and other reporting.  Read between the lines. This Trump administration, like them or not, is supporting infertility clinics. I bet they invest or support FEMY directly in 2026 with the declining birth rates. JMO.
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 7:25 PM
$FEMY eyes on support and bids!
0 · Reply
steve04240
steve04240 Jan. 13 at 4:54 PM
$FEMY where is our extension news?
0 · Reply
wolfden2000
wolfden2000 Jan. 13 at 4:42 PM
$FEMY Just some background. “Refuah” (רְפוּאָה) is Hebrew for healing or recovery. Refuah Health Center is a Federally Qualified Health Center (FQHC) — a nonprofit community medical organization providing comprehensive, affordable healthcare to people regardless of ability to pay. It primarily serves communities in Rockland, Sullivan, Orange, and Ulster Counties in New York, with multiple clinic sites including Spring Valley, South Fallsburg, and others. 
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 4:10 PM
$FEMY Partnership with Refuah Health Center https://www.rapidticker.com/news/femy-femasys-announces-partnership-with-refuah-99c052
0 · Reply
steve04240
steve04240 Jan. 13 at 3:12 PM
$FEMY boy oh boy Nothing like patience getting tested
0 · Reply
Ked1977
Ked1977 Jan. 13 at 2:44 PM
$FEMY so good news and price starts going down? Can someone explain?
1 · Reply
wolfden2000
wolfden2000 Jan. 13 at 2:36 PM
$FEMY ATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. The partnership is expected to strengthen Femasys’ commercial footprint in community-based fertility care by expanding patient access and supporting increased utilization of FemaSeed as a first-line approach. “This partnership is an important step forward in expanding the commercial availability of FemaSeed within community-based fertility care,” said Kathy Lee-Sepsick, Chief Executive Officer of Femasys. “With Refuah’s trusted care model and strong patient engagement, we expect to accelerate adoption of FemaSeed by providing a more accessible, cost-effective, and patient-centered starting point for fertility treatment.”
0 · Reply
beart00th
beart00th Jan. 13 at 2:30 PM
$FEMY Refueh Health Community-Based Care = Reoccurring Insurance $$$
0 · Reply
steve04240
steve04240 Jan. 13 at 2:19 PM
$FEMY
0 · Reply
DARKP00L
DARKP00L Jan. 13 at 2:11 PM
$FEMY 09:06 on Jan. 13 2026 Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process #tradeideas
0 · Reply
Bluesir
Bluesir Jan. 13 at 2:09 PM
$FEMY The offering is finally closed. We can start our climb from here. It’s time to see some strong green!
1 · Reply
DARKP00L
DARKP00L Jan. 13 at 2:09 PM
$FEMY 09:06 on Jan. 13 2026 Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process #tradeideas
0 · Reply
TripTrap
TripTrap Jan. 12 at 8:18 PM
$FEMY We will likely get news out later this afternoon or before the opening tomorrow on whether or not the NASDAQ has extended another six months to us to comply with the NASDAQ rule of being over a dollar. Today is January 12th - compliance deadline day. This could get interesting… Fingers crossed. 
1 · Reply